Medizinische Klinik

, Volume 92, Supplement 5, pp 37–40 | Cite as

Therapie des Asthma bronchiale: Antiinflammatorische Wirkungen von Antileukotrienen

  • Dieter Ukena
Article
  • 29 Downloads

Zusammenfassung

□ Die Antileukotriene, welche die Syntheseinhibitoren und die Leukotrien-Rezeptorantagonisten umfassen, repräsentieren eine neue Richtung in der zielgerichteten Asthma-Therapie. In dem vorliegenden Artikel werden die antünflammatorischen Eigenschaften der Antileukotriene kurz zusammengefaßta. Antileukotriene hemmen nach oraler Gabe die asthmatischen Früh- und Spätreaktionen nach Allergen-Provokation und können die Allergen-assoziierte bronchiale Hyperreagibilität vermindern. Sie weisen einen deutlichen Steroid-sparenden Effekt auf Beim chronischen Asthma entfalten die Antileukotriene einen signifikanten therapeutischen Benefit. Damit weisen die Antileukotriene zusätzlich zu ihren Eigenschaften als „Reliever“ auch solche von „Controllern“ des Asthmas auf.

Schlüsselwörter

Leukotriene Leukotrien-Rezeptorantagonist Leukotrien-Syntheseinhibitor Asthma 

Therapy of asthma: Anti-inflammatory effects of antileukotrienes

Summary

□ The antileukotrienes (anti-LT), consisting of synthesis inhibitors and leukotriene receptor antagonists, represent a new direction in targeted drug therapy for asthma. In the present article, the anti-inflammatory properties of anti-LT are briefly summarized. Orally administered anti-LT inhibit the allergen-induced early and late asthmatic reactions and may attenuate the allergen-associated hyperresponsiveness. They also have a remarkable inhaled steroid-sparing effect. In chronic asthma, anti-LT may exert significant therapeutic benefit. In addition to their properties as relievers, anti-LT may have properties as controllers of asthma.

Keywords

Leukotriene Leukotriene synthesis inhibitor Leukotriene receptor antagonist Asthma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Barnes, N. C., B. J. Lavins, C. J. Miller, J. Cohn, V. Perrin. Safety and tolerance of zafirlukast (Accolate ™), a new treatment for asthma. Am. J. Respir. Crit. Care Med. 155 (1997), A663.Google Scholar
  2. 2.
    Calhoun, W. J., K. L. Williams, S. G. Simonson, B. J. Lavins. Effect of zafirlukast (Accolate ®) on airway inflammation after segmental allergen challenge in patients with mild asthma. Am. J. Respir. Crit. Care Med. 155 (1997), A662.Google Scholar
  3. 3.
    Cumming, R. G., P. Mitchell, S. R. Leeder. Use of inhaled corticosteroids and the risk of cataracts. New Engl. J. Med. 337 (1997), 8–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Evans, D. J., P. J. Barnes, S. M. Spaethe, E. L. van Alstyne, M. I. Mitchell, B. J. O’Connor. Effect of a leukotriene B4 receptor antagonist, LY29311, on allergen induced responses in asthma. Thorax 51 (1996), 1178–1184.PubMedCrossRefGoogle Scholar
  5. 5.
    Findlay, S. R., J. M. Barden, C. B. Easley, M. Glass. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J. Allergy Clin. Immunol. 89 (1992), 1040–1045.PubMedCrossRefGoogle Scholar
  6. 6.
    Food and Drug Administration, US Department of Health and Human Services. FDA Talk Paper. Health advisory for new asthma drug. July 23, 1997.Google Scholar
  7. 7.
    Geddes, D. M. Inhaled corticosteroids: benefits and risks. Thorax 47 (1992), 404–407.PubMedCrossRefGoogle Scholar
  8. 8.
    Holgate, S. T., P. Bradding, A. P. Sampson. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J. Allergy Clin. Immunol. 98 (1996), 1–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Kane, G. C., M. Pollice, C.-J. Kim et al.: A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J. Allergy Clin. Immunol. 97 (1996), 646–654.PubMedCrossRefGoogle Scholar
  10. 10.
    Kelloway, J. S., R. A. Watt, S. A. Adlis. Comparison of patients’ compliance with prescribed oral and inhaled asthma medication. Arch. Intern. Med. 154 (1994), 1349–1352.PubMedCrossRefGoogle Scholar
  11. 11.
    Kohrogi, H., H. Iwagoe, K. Fujii et al.: The effect of leukotriene antagonist pranlukast on moderate and severe persistent asthma continues more than one year. Am. J. Respir. Crit. Care Med. 155 (1997), A662.Google Scholar
  12. 12.
    Kroegel, C., V. Herzog, B. Knöchel, P. Julius, W. Luttmann, J.-C. Virchow Jr. 5-Lipoxygenase-Inhibitoren und Leukotrien-Rezeptorantagonisten. Arzneimitteltherapie 14 (1996), 299–309.Google Scholar
  13. 13.
    Leff, J. A., E. Israel, M. J. Noonan, A. F. Finn et al.: Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stabilty. Am. J. Respir. Crit. Care Med. 155 (1997), A976.Google Scholar
  14. 14.
    Liu, M. C., L. M. Dube, J. Lancaster. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J. Allergy Clin. Immunol. 98 (1996), 859–871.PubMedCrossRefGoogle Scholar
  15. 15.
    O’Shaughnessy, K. M., I. K. Taylor, B. O’Connor, F. O’Connel, H. Thomson, C. T. Dollery. Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am. Rev. Respir. Dis. 147 (1993), 1431–1435.PubMedGoogle Scholar
  16. 16.
    Pedersen, S., P. O’Byrne. A comparison of the efficacy and safety of inhaled coticosteroids in asthma. Allergy 52, Suppl. 39 (1997), 1–34.PubMedCrossRefGoogle Scholar
  17. 17.
    Reiss, T. F., P. Chervinsky, T. Edwards, R. Dockhorn et al.: Montelukast (MK-0476), a cystLT1 receptor antagonist, improves asthma outcomes over a 3-month treatment period. Am. J. respir. Crit. Care Med. 155 (1997), A 662.Google Scholar
  18. 18.
    Rosenthal, R., B. J. Lavins, L.A. Hanby. Effect of treatment with zafirlukast (Accolate TM) on bronchial hyper-responsiveness in patients with mild-to-moderate asthma. J. Allergy Clin. Immunol. 97 (1996), A270.Google Scholar
  19. 19.
    Sahn, S., S. Galant, J. Murray, E. Bronsky, S. Spector, I. Faiferman, P. Stober. Pranlukat (Ultair TM) improves FEV1 in patients with asthma: results ofa 12-week multicenter study vs nedocromil. Am. J. Respir. Crit. Care Med. 155 (1997), A665.Google Scholar
  20. 20.
    Tarnaoki, J., M. Kondo, N. Sakai, J. Nakata, H. Takemura, A. Nagai, T. Takizawa, K. Konno. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am. J. Respir. Crit. Care Med. 155 (1997), 1235–1240.Google Scholar
  21. 21.
    Taylor, I. K., K. M. O’Shaughnessy, R. W. Fuller, C. T. Dollery. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337 (1991), 690–694.PubMedCrossRefGoogle Scholar
  22. 22.
    Ukena, D., A. Keller, G. W. Sybrecht. Theophyllin. Neues zu einem bewährten Medikament. Die duale Wirkung in der Therapie des Asthma bronchiale. Med. Klin. 89 (1994), 668–674.Google Scholar
  23. 23.
    Ukena, D., G. W. Sybrecht: Die Bedeutung von Modulatoren des Leukotrien-Stoffwechsels für die Asthma-Therapie. Atemw. Lungenkrh. 21 (1995), 37–43.Google Scholar
  24. 24.
    Virchow, J. C., A. Prasse, H. Matthys. Vergleich von Theophyllin mit Antagonisten des Mediatorstoffwechsels. In: Ukena D., A. Keller, D. Nolte (Hrsg.): Theophyllin — Controller und Reliever bei Asthma und COPD. Dustri-Verlag, München 1996, S. 40–75.Google Scholar
  25. 25.
    Wenzel, S. E., J. B. Trudeau, D. A. Kaminsky, J. Cohn, R. J. Martin, J. Y. Westcott. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am. J. Respir. Crit. Care Med. 152 (1995), 897–905.PubMedGoogle Scholar
  26. 26.
    Wenzel, S., P. Chervinsky, E. Kerwin, W. Silvers, I. Faiferman, J. Dubb. Oral pranlukast (Ultair TM) vs inhaled beclomethasone: results of a 12-week trial in patients with asthma. Am. J. Respir. Crit. Care Med. 155 (1997), A203.Google Scholar

Copyright information

© Urban & Vogel 1997

Authors and Affiliations

  • Dieter Ukena
    • 1
  1. 1.Medizinische UniversitätsklinikInnere Medizin VHomburg

Personalised recommendations